Anderson I M (2004) Drug information not regulation is needed . J Psychopharmacol18: 11–12
2.
Bailey J (2004) The application of good clinical practice to challenge tests . J Psychopharmacol18: 13
3.
Cuervo L G, Clarke M (2003) Balancing benefits and harms in health care . BMJ327: 65–66
4.
Gijsman H J, Van Gerven J M A, Schoemaker R C, Ferrari M D (1997) Meta-chlorophenylpiperazine (m-cpp) is no useful tool for migraine provocation . Cephalalgia17: 390–391
5.
Gijsman H J, Van Gerven J M A, Tieleman M C, Schoemaker R C, Pieters M S M, Ferrari M D, Cohen A F, Van Kempen G M J (1998) Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers . J Clin Psycho-pharmacol18: 289–294
6.
Gijsman H J, Van Gerven J M A, De Kam M L, Schoemaker R C, Pieters M S M, Weemaes M, De Rijk R H, Van der Post J, Cohen A F (2002) Placebo-controlled comparison of three dose-regimens of 5-hydroxy-tryptophan challenge test in healthy volunteers . J Clin Psychopharmacol22: 183–189
7.
Pinder R M (2004) The application of the principles of clinical drug development to a pharmacological challenge test of the serotonergic system . J Psychopharmacol18: 15
8.
Silverstone P H, Cowen P J (1994) The 5-HT3 antagonist, BRL 46470 does not attenuate m-chlorophenylpiperazine (m-cpp)-induced changes in human volunteers . Biol Psychiatry36: 309–316
9.
Silverstone P H, Rue J E, Franklin M, Hallis K, Campling G M, Laver D, Cowen P J (1994) The effects of administration of m-cpp on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers . Int Clin Psychopharmacol9: 173–178
